Short name: SHU 555 C, preliminary trade name: Supravist™
An ultrasmall superparamagnetic iron oxide under development as a positive enhancing blood pool agent (MRI contrast agent phase III, Bayer Schering Pharma AG). Supravist™ can be administered as an iv. bolus up to doses of 80 μmol/kg.

See also Ultrasmall Superparamagnetic Iron Oxide and Blood Pool Agents.

The Germany-based pharmaceutical company is the result of the take-over of Schering AG by Bayer AG in 2006. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group. Activities of the Bayer Schering Pharma AG are Diagnostic Imaging, Hematology and Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. The diagnostic imaging part's contrast agents for MRI, x-ray and computed tomography are 'world-market leaders'.

MRI Contrast Agents:

Short name: SHU 555 C, preliminary trade name: Supravist™, concentration: 0.5 mol Fe/L
SHU 555 C (Bayer Schering Pharma AG), a contrast agent under development for MRA, is an optimized formulation with respect to T1 weighted MRI of the carboxydextran-coated ferucarbotran (see also Resovist® formerly SHU 555 A, Bayer Schering Pharma AG).